
Region:Middle East
Author(s):Sanjeev
Product Code:KROD4726
October 2024
85
The Saudi Arabia OTC drugs market is valued at USD 1.15 billion, driven by the increasing trend of self-medication, ease of access to non-prescription drugs, and a growing number of pharmacies across the country. Factors like the rising healthcare costs, an expanding middle class, and the preference for self-care and convenience have propelled the demand for OTC drugs in recent years. The market has been steadily growing as more pharmaceutical companies develop new products that meet regulatory standards for over-the-counter availability.
Riyadh, Jeddah, and Dammam are the dominant cities in the Saudi OTC drugs market, owing to their higher population density, economic prosperity, and advanced healthcare infrastructure. These urban centers have a high number of pharmacies and healthcare providers, making OTC drugs more accessible. Furthermore, these cities attract more tourists, which increases demand for general healthcare products, including OTC drugs.
The SFDA continues to be the main regulatory body overseeing the OTC drugs market. In 2023, the SFDA revised its regulatory framework, introducing new guidelines to improve the safety and efficacy of OTC drugs. These guidelines include stricter labeling requirements, ensuring that consumers are better informed about product usage. This has also led to the withdrawal of over 50 non-compliant products in 2023.
By Drug Type: The market is segmented by drug type into analgesics, cold, cough & flu remedies, digestive remedies, dermatology products, and vitamins & minerals. Analgesics have a dominant market share within this segment. This dominance is due to the widespread prevalence of pain-related issues such as headaches, muscle pain, and minor injuries among the population. Additionally, analgesics are frequently recommended by healthcare professionals and are considered safe for self-medication, making them a common choice among consumers.
By Distribution Channel: The market is segmented by distribution channels into pharmacies, supermarkets/hypermarkets, online retailers, and health & wellness stores. Pharmacies dominate the distribution channel segment. The dominance of pharmacies can be attributed to their role as the primary source of OTC drugs in Saudi Arabia. Pharmacies provide consumers with expert advice from pharmacists and easy access to a wide range of OTC products. Furthermore, the expanding pharmacy network in both urban and rural areas has contributed to the dominance of this distribution channel.

The Saudi Arabia OTC drugs market is dominated by a mix of multinational and local companies that have a strong presence in the country. Key players include Sanofi, GlaxoSmithKline, Johnson & Johnson, Pfizer, and Novartis, each leveraging their global expertise and extensive product portfolios to maintain a competitive edge. The consolidation of these market players highlights their significant influence and the competitive nature of the Saudi market.
|
Company |
Established |
Headquarters |
Number of Employees |
Revenue (USD Bn) |
Product Portfolio |
R&D Investment (USD Mn) |
Key Clients |
Global Reach |
Technological Innovations |
|
Sanofi |
1973 |
Paris, France |
|
|
|
|
|
|
|
|
GlaxoSmithKline (GSK) |
2000 |
Brentford, UK |
|
|
|
|
|
|
|
|
Johnson & Johnson |
1886 |
New Brunswick, USA |
|
|
|
|
|
|
|
|
Pfizer |
1849 |
New York, USA |
|
|
|
|
|
|
|
|
Novartis |
1996 |
Basel, Switzerland |
|
|
|
|
|
|
|
Increasing Self-Medication: The rising cost of healthcare services in Saudi Arabia is driving more individuals toward self-medication. The average healthcare expenditure per capita in the country is estimated at $1,200, with a significant portion of the population opting for OTC drugs as a cost-effective alternative. The Ministry of Health's reports highlight a growing reliance on self-treatment due to the affordability and accessibility of OTC products. This is further influenced by the rising out-of-pocket expenses on healthcare, as noted in the World Bank's 2023 report on healthcare financing.
Expanding Pharmacy Network: The expansion of pharmacy networks, especially in rural and underserved areas, has significantly boosted the availability of OTC drugs in Saudi Arabia. There are currently over 9,000 registered pharmacies across the country, up from 7,500 in 2020, according to the Saudi Food and Drug Authority (SFDA). Increased access to these pharmacies has allowed consumers in remote regions to procure OTC medications more easily, reflecting a steady improvement in infrastructure and healthcare service delivery.
Regulatory Support: The Saudi government plays a pivotal role in the OTC drug market, particularly through the SFDA’s streamlined approval processes. As of 2024, the SFDA has approved over 2,000 OTC products, facilitating easier market entry for pharmaceutical companies. Government policies, including Vision 2030’s emphasis on improving healthcare accessibility, further support this growth, ensuring quicker and more efficient drug approvals while maintaining stringent quality checks.
Strict Regulatory Requirements: While government support exists, the SFDA's stringent regulations pose challenges to OTC drug manufacturers. As of 2024, the SFDA has tightened its regulations on labeling, ingredients, and safety protocols, leading to delays in product launches. Currently, over 200 applications for OTC products are pending approval due to regulatory scrutiny. This has created a bottleneck for companies trying to introduce new products to the market, despite the high demand.
Competition from Prescription Drugs: The shift from prescription (Rx) to OTC drugs has been gradual in Saudi Arabia, with some consumers continuing to rely on Rx products. There were over 5,000 prescription medications approved by the SFDA in 2023, making competition with OTC products intense. Additionally, the health system’s preference for Rx treatments for more serious conditions poses a challenge for OTC market penetration.
Over the next five years, the Saudi Arabia OTC drugs market is expected to witness substantial growth, driven by the increasing demand for self-medication products, government initiatives to improve healthcare access, and the growing presence of e-commerce platforms in the pharmaceutical sector. Additionally, technological advancements, such as the rise of digital pharmacies, are likely to shape the future of the market. The increasing consumer preference for preventive healthcare and wellness products, particularly in urban centers, will further drive market expansion.
|
By Drug Type |
Analgesics Cold, Cough & Flu Remedies Digestive Remedies Dermatology Products Vitamins & Minerals
|
|
By Distribution Channel |
Pharmacies Supermarkets/Hypermarkets Online Retailers Health & Wellness Stores |
|
By Formulation |
Tablets Capsules Liquids Powders |
|
By Consumer Group |
Adults Children Geriatrics |
|
By Region |
North East West South |
1.1. Definition and Scope
1.2. Market Taxonomy
1.3. Market Growth Rate
1.4. Market Segmentation Overview
2.1. Historical Market Size
2.2. Year-On-Year Growth Analysis
2.3. Key Market Developments and Milestones
3.1. Growth Drivers
????3.1.1. Increasing Self-Medication (Rising healthcare costs, Growing preference for self-treatment)
????3.1.2. Expanding Pharmacy Network (Access to OTC drugs in rural and urban areas)
????3.1.3. Regulatory Support (Government's role in OTC drug approvals)
????3.1.4. Rising Healthcare Awareness (Increased health literacy and awareness campaigns)
3.2. Market Challenges
????3.2.1. Strict Regulatory Requirements (Saudi Food and Drug Authority regulations)
????3.2.2. Competition from Prescription Drugs (Switch from Rx to OTC)
????3.2.3. Consumer Misinformation (Misuse and improper self-diagnosis)
3.3. Opportunities
????3.3.1. Online Pharmacy Growth (E-commerce in pharmaceuticals)
????3.3.2. OTC Drug Market Expansion (Introduction of new product lines)
????3.3.3. Innovation in Product Forms (Gummies, dissolvable tablets)
3.4. Trends
????3.4.1. Digital Health Integration (Telemedicine and OTC drug sales)
????3.4.2. Increased Consumer Preference for Natural Products (Herbal and organic OTC products)
????3.4.3. Health and Wellness Products (Shift toward vitamins, supplements, and probiotics)
3.5. Government Regulation
????3.5.1. Saudi Food and Drug Authority (SFDA) Regulations
????3.5.2. OTC Drug Approval Process
????3.5.3. Import and Export Policies
3.6. SWOT Analysis (Market-specific strengths, weaknesses, opportunities, threats)
3.7. Stakeholder Ecosystem (Suppliers, Distributors, Retailers, Consumers)
3.8. Porter’s Five Forces (Bargaining power of suppliers, buyers, competitive rivalry, threat of new entrants, and substitutes)
3.9. Competition Ecosystem (Key players, market positioning)
4.1. By Drug Type (In Value %)
????4.1.1. Analgesics
????4.1.2. Cold, Cough & Flu Remedies
????4.1.3. Digestive Remedies
????4.1.4. Dermatology Products
????4.1.5. Vitamins & Minerals
4.2. By Distribution Channel (In Value %)
????4.2.1. Pharmacies
????4.2.2. Supermarkets/Hypermarkets
????4.2.3. Online Retailers
????4.2.4. Health & Wellness Stores
4.3. By Formulation (In Value %)
????4.3.1. Tablets
????4.3.2. Capsules
????4.3.3. Liquids
????4.3.4. Powders
4.4. By Consumer Group (In Value %)
????4.4.1. Adults
????4.4.2. Children
????4.4.3. Geriatrics
4.5. By Region (In Value %)
????4.5.1. Riyadh
????4.5.2. Jeddah
????4.5.3. Makkah
????4.5.4. Dammam
????4.5.5. Eastern Province
5.1. Detailed Profiles of Major Companies
????5.1.1. Sanofi
????5.1.2. GlaxoSmithKline (GSK)
????5.1.3. Johnson & Johnson
????5.1.4. Novartis
????5.1.5. Bayer AG
????5.1.6. Pfizer
????5.1.7. Reckitt Benckiser
????5.1.8. Abbott Laboratories
????5.1.9. Procter & Gamble
????5.1.10. Merck
????5.1.11. Takeda Pharmaceutical Company
????5.1.12. Boehringer Ingelheim
????5.1.13. Taisho Pharmaceutical
????5.1.14. Sun Pharmaceutical Industries
????5.1.15. Glanbia
5.2. Cross Comparison Parameters (Product Portfolio, Market Presence, Revenue, R&D Investments, Strategic Initiatives, Number of Patents, Market Share)
5.3. Market Share Analysis (Based on revenue contribution)
5.4. Strategic Initiatives (New product launches, partnerships, collaborations)
5.5. Mergers and Acquisitions
5.6. Investment Analysis (Private equity, venture capital, corporate investments)
5.7. Government Grants and Subsidies
5.8. Private Equity Investments
6.1. SFDA Compliance
6.2. Product Registration and Licensing
6.3. Advertising Regulations
6.4. Labeling and Packaging Standards
7.1. Future Market Size Projections
7.2. Key Factors Driving Future Market Growth
8.1. By Drug Type (In Value %)
8.2. By Distribution Channel (In Value %)
8.3. By Formulation (In Value %)
8.4. By Consumer Group (In Value %)
8.5. By Region (In Value %)
9.1. TAM/SAM/SOM Analysis
9.2. Customer Cohort Analysis
9.3. White Space Opportunity Analysis
9.4. Marketing Initiatives
The initial phase involves identifying the core variables impacting the Saudi Arabia OTC drugs market. This includes understanding the regulatory framework, consumer behavior, and key industry trends. Extensive desk research and the use of secondary and proprietary databases were utilized to gather critical data.
In this step, historical data on the Saudi Arabia OTC drugs market was compiled, including drug type performance, distribution channel penetration, and sales volumes. Detailed data analysis was conducted to assess the current market structure and future growth prospects.
To validate market assumptions, consultations with industry experts from leading OTC drug manufacturers, distributors, and regulatory bodies were conducted through phone interviews. This step helped refine and verify market estimates and trends.
In the final phase, comprehensive insights were gathered through collaboration with various stakeholders in the Saudi pharmaceutical industry. This included product analysis, market share validation, and future projections, ensuring a comprehensive and reliable analysis of the OTC drugs market.
The Saudi Arabia OTC drugs market is valued at USD 1.15 billion, driven by increasing self-medication practices, growing consumer awareness, and an expanding network of pharmacies.
Challenges in Saudi Arabia OTC drugs market include strict regulatory requirements from the Saudi Food and Drug Authority (SFDA), intense competition from both local and global players, and the threat of counterfeit OTC products impacting brand trust and safety.
Key players in the Saudi Arabia OTC drugs market include Sanofi, GlaxoSmithKline (GSK), Johnson & Johnson, Pfizer, and Novartis. These companies dominate the market through their extensive product portfolios, established brand presence, and strong distribution networks.
The Saudi Arabia OTC drugs market is driven by the rising demand for self-medication, the growth of e-commerce platforms selling pharmaceuticals, and consumer preferences for convenience and preventive healthcare products.
The Saudi Food and Drug Authority (SFDA) plays a crucial role in regulating the approval, marketing, and distribution of OTC drugs. It ensures that products meet safety standards and comply with advertising regulations, maintaining consumer trust in the market.
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.